EVOLITO
22.9.2021 13:17:13 CEST | Business Wire | Press release
Evolito, a new company developing and manufacturing electric motors and power electronics for aerospace applications, launched publicly today as a privately-owned business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005519/en/
Evolito was spun out earlier this year by YASA (the world-leading pioneer of automotive axial-flux electric motors acquired by Mercedes-Benz in July 2021) to exclusively commercialise YASA’s next-generation electric motor technology and IP for the rapidly-growing aerospace market.
The business’s axial-flux motor technology has been proven in volume series production in the automotive industry and has even greater advantages in the aerospace market. As such, Evolito is uniquely positioned to drive forward the commercialisation and adoption of electric flight.
Evolito’s ultra high-performance, low-weight axial-flux motors and power electronics are smaller, lighter and more robust than any other competing technology, opening up a range of new opportunities for Electric Vertical Take-off and Landing (eVTOL), Fixed Wing and distributed electric propulsion applications such as Urban Air Mobility (UAM).
The unique segmented topology of the Evolito motor is inherently more robust than other electric motor approaches, making it ideally suited to the demands of the aerospace market where safety is paramount.
Cyrus Jilla, Partner and Board Director, Waypoint Capital said, “At Waypoint, one of our thematic interests is in energy transition and sustainability, including electrification. We look to invest in businesses with unique disruptive technology led by outstanding teams. Evolito is a perfect fit for us and we look forward to backing the team as they develop their game-changing electrification solutions for the aerospace market, making emissions-free flight a reality.”
Alexis Zervoglos, Senior Partner, OSE said, “The electrification of flight is one of the most exciting market opportunities of our time. Realising this potential will require innovative new technology and an ability to scale to meet the fast-emerging demand. OSE is delighted to be supporting Evolito on its mission to accelerate the adoption of electric flight.”
Gareth Morris, Managing Director, Evolito said, “Electrification in aerospace is some ten years behind that of the automotive industry, but the market potential is huge. Electric Vertical Take-off and Landing, Electric Helicopter, Fixed-Wing and Urban Air Mobility aircraft need high power density, low weight electric powertrains with inherently high safety factors - a combination of attributes that are unique to our axial-flux electric motor and power electronics. By leveraging YASA’s unique IP in the aerospace market, Evolito will fast-track the commercialisation of electric flight and transform mobility as we know it.”
EDITOR’S NOTES
Electric drive solutions for the Urban Air Mobility market are forecast to grow to USD $90 billion and 160,000 vehicles by 2050. Source: Roland Berger “The high-flying industry: Urban Air Mobility takes off” , Nov, 2020.
Evolito http://www.evolito.co.uk/
Evolito is making all-electric flight a commercial reality with world-leading direct-drive electric propulsion solutions. Spun out of YASA in 2021, Evolito leverages technology proven by OEMs in the EV industry. Evolito’s axial-flux electric motors and power electronics offer the highest power and torque densities in class – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications – and is inherently more robust than competing technologies. The privately-held company is based in Oxford. Evolito’s investors include Waypoint Capital and Oxford Science Enterprises (OSE).
YASA http://www.yasa.com/
YASA, part of Mercedes-Benz AG, is a pioneer in next-generation electric drive technology. YASA’s unique axial-flux electric motor technology offers the greatest efficiencies and highest power densities in class for the smallest size and weight. YASA is based in Oxford and Welshpool, UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005519/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom